Emerging molecular targeted therapies in the treatment of head and neck cancer

Expert Opinion on Emerging Drugs

Volumn 14, Issue 2, 2009, Pages 299-310

  Bozec, Alexandre ^a   Peyrade, Frédéric ^a   Fischel, Jean Louis ^a   Milano, Gérard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Angiogenesis; Cetuximab; EGFR; Head and neck squamous cell carcinoma; Molecular targeted therapies

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANTINEOPLASTIC METAL COMPLEX; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CELECOXIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; HYDROXYUREA; LAPATINIB; METHOTREXATE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; N ACETYLCOLCHINOL PHOSPHATE; PACLITAXEL; PANITUMUMAB; RAPAMYCIN; SEMAXANIB; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VECTBIX;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG POTENTIATION; DRUG PROTEIN BINDING; HEAD AND NECK CARCINOMA; HUMAN; METASTASIS; MUCOSA INFLAMMATION; NONHUMAN; PATIENT COMPLIANCE; PROTEIN TARGETING; RASH; RECURRENT CANCER; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; THROMBOEMBOLISM; TREATMENT INDICATION; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; HEAD AND NECK NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 67649371250     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210902997947     Document Type: Review

References (107)

1. Ragin CC, Modugno F, Gollin SM. The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 2007;86(2):104-114
2. Dassonville O, Bozec A, Fischel JL, Milano G. EGFR-targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol 2007;62(1):53-61
3. Dassonville O, Formento JL, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993;11(10):1873-1878 (Pubitemid 23304610)
4. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23(11):2445-2459 (Pubitemid 47050835)
5. Bozec A, Poissonnet G, Chamorey E, et al. Free-flap head and neck reconstruction and quality of life: a 2-year prospective study. Laryngoscope 2008;118(5):874-880 (Pubitemid 351631286)
6. Harari PM. Promising new advances in head and neck radiotherapy. Ann Oncol 2005;16(Suppl 6):vi13-9 (Pubitemid 41487946)
7. Pignon JP, le Maitre A, Bourhis J. Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007;69(2 Suppl):S112-4
8. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357(17):1705-1715 (Pubitemid 350005152)
9. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357(17):1695-1704 (Pubitemid 350005151)
10. Poissonnet G, Benezery K, Peyrade F, et al. Upper aerodigestive tract carcinoma: therapeutic management. Presse Med 2007;36(11 Pt 2):1634-1642 (Pubitemid 47588783)
11. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008;371(9625):1695-1709 (Pubitemid 351671886)
12. Gold KA, Lee HY, Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 2009;115(5):922-935
13. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567-578 (Pubitemid 43209104)
14. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23(24):5578-5587 (Pubitemid 46300152)
15. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23(24):5568-5577 (Pubitemid 46300151)
16. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23(34):8646-8654 (Pubitemid 46211507)
17. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-1127
18. Merck Annual Report 2007. Merck Serono - Markets - Oncology 2007. Available from: www.reports.merck.de/2007/ar/managementreportdivisions/ merckserono/markets/oncology.html
19. Erbitux will reach US$ 250 million in sales in 2015, a five-fold increase in the value of the entire 2005 head and neck cancer drug market. Press Releases 2006. Available from: www.pharmalicensing.com/public/press/view/ 1163428872-45588408ed4af/erbitux-will-reach-us-250-million-in-salesin-2015-a- five-fold-increase-in-the-value-of-the-entire-2005-head-and-neck-cancer-drug- market
20. Wang LX, Agulnik M. Promising newer molecular-targeted therapies in head and neck cancer. Drugs 2008;68(12):1609-1619
21. Molinolo AA, Amornphimoltham P, Squarize CH, et al. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 2008; In press, doi:10.1016/j.oraloncology.2008.07.011
22. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53(15):3579-3584 (Pubitemid 23229640)
23. Ciardiello F. Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncol 2005;1(2):221-234
24. Iwase M, Takaoka S, Uchida M, et al. Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells. Oral Oncol 2008;44(4):361-368
25. Bozec A, Formento P, Ciccolini J, et al. Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. Mol Cancer Ther 2005;4(12):1962-1971 (Pubitemid 43056979)
26. Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002;62(9):2554-2560 (Pubitemid 34462734)
27. Taylor RJ, Chan SL, Wood A, et al. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2008; In press, doi:10.1007/s00262-008-0613-3
28. Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc) 2003;39(Suppl C):1-16 (Pubitemid 37509400)
29. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1(2):118-129 (Pubitemid 33741887)
30. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23(5):1011-1027 (Pubitemid 46202320)
31. Bock JM, Sinclair LL, Bedford NS, et al. Modulation of cellular invasion by VEGF-C expression in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2008;134(4):355-362 (Pubitemid 351581082)
32. Siemann DW, Bibby MC, Dark GG, et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005;11(2 Pt 1):416-420 (Pubitemid 40116863)
33. Bozec A, Gros FX, Penault-Llorca F, et al. Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition. Eur J Cancer 2008;44(13):1922-1930
34. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10(2):415-427 (Pubitemid 38173977)
35. Bozec A, Lassalle S, Gugenheim J, et al. Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126. Br J Cancer 2006;95(6):722-728 (Pubitemid 44373488)
36. Bianco C, Tortora G, Bianco R, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002;8(10):3250-3258 (Pubitemid 35155038)
37. Magne N, Fischel JL, Dubreuil A, et al. Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 2002;86(5):819-827 (Pubitemid 34250828)
38. Hagan M, Yacoub A, Dent P. Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma. Clin Cancer Res 2004;10(17):5724-5731 (Pubitemid 39180948)
39. Bozec A, Thariat J, Bensadoun RJ, Milano G. Chemoradiotherapy in head and neck squamous cell carcinoma: focus on targeted therapies. Cancer Radiother 2008;12(1):14-24
40. Cao C, Albert JM, Geng L, et al. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer Res 2006;66(23):11409-11415 (Pubitemid 46009972)
41. Bozec A, Sudaka A, Fischel JL, et al. Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. Br J Cancer 2008;99(1):93-99 (Pubitemid 351920227)
42. Bozec A, Formento P, Lassalle S, et al. Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts. Br J Cancer 2007;97(1):65-72 (Pubitemid 47012080)
43. Ning S, Laird D, Cherrington JM, Knox SJ. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 2002;157(1):45-51 (Pubitemid 34073387)
44. Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002;53(1):164-171 (Pubitemid 34465821)
45. Wachsberger PR, Burd R, Marero N, et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 2005;11(2 Pt 1):835-842 (Pubitemid 40116912)
46. Kondo N, Ishiguro Y, Kimura M, et al. Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab. Oncol Rep 2008;20(2):373-378
47. Montemurro F, Valabrega G, Aglietta M. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 2007;7(2):257-268 (Pubitemid 46192173)
48. Herbst RS, Heymach JV, O'Reilly MS, et al. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 2007;16(2):239-249 (Pubitemid 46206638)
49. Sano D, Kawakami M, Fujita K, et al. Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncol Rep 2007;17(2):289-295
50. Gustafson DL, Frederick B, Merz AL, Raben D. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. Cancer Chemother Pharmacol 2008;61(2):179-188 (Pubitemid 350160317)
51. Zhang Q, Thomas SM, Xi S, et al. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004;64(17):6166-6173 (Pubitemid 39129418)
52. Koppikar P, Choi SH, Egloff AM, et al. Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res 2008;14(13):4284-4291
53. Kijima T, Niwa H, Steinman RA, et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ 2002;13(8):355-362 (Pubitemid 34941068)
54. Boehm AL, Sen M, Seethala R, et al. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol Pharmacol 2008;73(6):1632-1642
55. Amornphimoltham P, Patel V, Leelahavanichkul K, et al. A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer. Cancer Res 2008;68(4):1144-1153 (Pubitemid 351272233)
56. Aissat N, Le Tourneau C, Ghoul A, et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008;62(2):305-313 (Pubitemid 351692089)
57. Le Tourneau C, Siu LL. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Curr Opin Oncol 2008;20(3):256-263
58. Barnes CJ, Ohshiro K, Rayala SK, et al. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 2007;13(14):4291-4299
59. Bonner JA. Prolongation of survival with the addition of cetuximab to radiation in patients with locoregionally advanced head and neck cancer (SCCHN): five-year results from a randomized trial. Presented at: American Society for Therapeutic Radiology and Oncology's 50th Annual Meeting, Boston, 2008 September 21-25
60. Bernier J, Bonner J, Vermorken JB, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008;19(1):142-149
61. Le Tourneau C, Chen EX. Molecularly targeted agents in the treatment of recurrent or metastatic squamous cell carcinomas of the head and neck. Hematol Oncol Clin North Am 2008;22(6):1209-20, ix
62. Langer CJ. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer 2008;112(12):2635-2645
63. Lopez-Albaitero A, Ferris RL. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 2007;133(12):1277-1281 (Pubitemid 350294259)
64. Kruser TJ, Armstrong EA, Ghia AJ, et al. Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer. Int J Radiat Oncol Biol Phys 2008;72(2):534-542
65. Dietz A, Boehm A, Mozet C, et al. Current aspects of targeted therapy in head and neck tumors. Eur Arch Otorhinolaryngol 2008;265(Suppl 1):S3-12
66. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20(21):4292-4302 (Pubitemid 35266289)
67. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22(1):77-85 (Pubitemid 41095117)
68. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21(10):1980-1987 (Pubitemid 46606387)
69. Belon J, Irigoyen A, Rodriguez I, et al. Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck [abstract 5563]. J Clin Oncol 2005;23(Suppl)
70. Kim ES, Kies M, Glisson BS, et al. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent / metastatic head and neck cancer [abstract 6013]. J Clin Oncol 2007;25(Suppl)
71. Wirth LJ, Haddad RI, Lindeman NI, et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23(28):6976-6981 (Pubitemid 46260283)
72. Abidoye OO, Cohen EE, Wong SJ, et al. A phase II study of lapatinib (GW572016) in recurrent / metastatic squamous cell carcinoma of the head and neck [abstract 5568]. J Clin Oncol 2006;24(Suppl)
73. Available from: www.clinicaltrials.gov
74. Cooney MM, Tserng KY, Makar V, et al. A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. Cancer Chemother Pharmacol 2005;55(3):295-300 (Pubitemid 40142895)
75. Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007;25(24):3766-3773 (Pubitemid 47372619)
76. Seiwert TY, Haraf DJ, Cohen EE, et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol 2008;26(10):1732-1741
77. Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009;10(3):247-257
78. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006;24(7):1072-1078 (Pubitemid 46638804)
79. Suntharalingam M, Taylor R, Wolf J. Initial report of phase II trial of weekly cetuximab, CBDCA, paclitaxel and daily radiotherapy in patients with locally advanced SCCHN. Presented at: Multidisciplinary head and neck cancer symposium, California, 2007 January 18-20
80. Zhang Y, Ma QY, Dang CX, et al. Quantitative molecular diagnosis of axillary drainage fluid for prediction of locoregional failure in patients with one to three positive axillary nodes after mastectomy without adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2006;64(2):505-511 (Pubitemid 43083439)
81. Decker D, Tolba R, Springer W, et al. Abdominal surgical interventions: local and systemic consequences for the immune system - a prospective study on elective gastrointestinal surgery. J Surg Res 2005;126(1):12-18 (Pubitemid 40726240)
82. Guller U, Zajac P, Schnider A, et al. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 2002;236(6):768-75; discussion 775-776 (Pubitemid 35403232)
83. Delord J, Thomas A, Benlyazid J, et al. Neo-adjuvant treatment with erlotinib in squamous cell carcinoma head and neck (SCCHN) patients before surgery provides an opportunity to find predictive factors of response [abstract 5513]. J Clin Oncol 2006;18(Suppl)
84. Grandis JR, Lai SY, Esteve FR, et al. Erlotinib (E) as adjuvant treatment for patients (pts) with resected head and neck squamous cell carcinoma (HNSCC) with evaluation of neoadjuvant biomarker modulation with E with or without sulindac (S): a feasibility report [abstract 6037]. J Clin Oncol 2008;20(Suppl)
85. Savvides P, Greskovich J, Bokar JA, et al. Phase II study of bevacizumab with docetaxel and radiation in locally advanced head and neck squamous cell cancer [abstract 6071]. J Clin Oncol 2008;20(Suppl)
86. Kies MS, Gibson MK, Kim SW, et al. Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN): an interim analysis [abstract 6072]. J Clin Oncol 2008;20(Suppl)
87. Forastiere AA, Burtness BA. Epidermal growth factor receptor inhibition in head and neck cancer-more insights, but more questions. J Clin Oncol 2007;25(16):2152-2155 (Pubitemid 46954634)
88. Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007;25(16):2164-2170 (Pubitemid 46954638)
89. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24(25):4170-4176 (Pubitemid 46622295)
90. Willmore-Payne C, Holden JA, Layfield LJ. Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Mod Pathol 2006;19(5):634-640
91. Huang HS, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997;272(5):2927-2935 (Pubitemid 27053343)
92. Wikstrand CJ, Hale LP, Batra SK, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995;55(14):3140-3148
93. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 1997;57(18):4130-4140 (Pubitemid 27427708)
94. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12(17):5064-5073 (Pubitemid 44453332)
95. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66(8):3992-3995
96. Ichikawa T, Yano Y, Uchida M, et al. The activation of K-ras gene at an early stage of lung tumorigenesis in mice. Cancer Lett 1996;107(2):165-170 (Pubitemid 26381984)
97. Yamashita N, Minamoto T, Ochiai A, et al. Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. Gastroenterology 1995;108(2):434-440
98. Yarbrough WG, Shores C, Witsell DL, et al. ras mutations and expression in head and neck squamous cell carcinomas. Laryngoscope 1994;104(11 Pt 1):1337-1347 (Pubitemid 24346961)
99. Matsuda H, Konishi N, Hiasa Y, et al. Alterations of p16/CDKN2, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions. J Oral Pathol Med 1996;25(5):232-238 (Pubitemid 126447416)
100. Saranath D, Chang SE, Bhoite LT, et al. High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br J Cancer 1991;63(4):573-578
101. Spencer JM, Kahn SM, Jiang W, et al. Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas. Arch Dermatol 1995;131(7):796-800
102. McDonald JS, Jones H, Pavelic ZP, et al. Immunohistochemical detection of the H-ras, K-ras, and N-ras oncogenes in squamous cell carcinoma of the head and neck. J Oral Pathol Med 1994;23(8):342-346 (Pubitemid 2150698)
103. Hoa M, Davis SL, Ames SJ, Spanjaard RA. Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma. Cancer Res 2002;62(24):7154-7156 (Pubitemid 36025228)
104. Atkinson DM, Clarke MJ, Mladek AC, et al. Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts. Head Neck 2008;30(6):790-799 (Pubitemid 351913857)
105. Penault-Llorca F, Bibeau F, Arnould L, et al. EGFR expression in colorectal cancer and role in tumorigenesis. Bull Cancer 2005;92(Spec no):S5-11 (Pubitemid 43046493)
106. Agulnik M, da Cunha Santos G, Hedley D, et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 2007;25(16):2184-2190 (Pubitemid 46954641)
107. Calvo E, Malik SN, Siu LL, et al. Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer. Ann Oncol 2007;18(4):761-767 (Pubitemid 46523282)